Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo

2021/10/19 by Guodi Liu, Qian Zhang, Guoping Liu +7 · 20 citations
Medicine · Biochemistry, Genetics and Molecular Biology · Engineering · #CAR-T cell therapy research #Virus-based gene therapy research #Silicon Carbide Semiconductor Technologies

paper · doi:10.1016/j.yexcr.2021.112886

Citations

• Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Cited by

• Mesothelin: An Immunotherapeutic Target beyond Solid Tumors. [europepmc]
• Targeting purine metabolism in ovarian cancer. [europepmc]
• Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed. [europepmc]
• Strategies to enhance CAR-T persistence. [europepmc]
• RNA Therapeutics for Improving CAR T-cell Safety and Efficacy. [europepmc]
• CD39/CD73/A2AR pathway and cancer immunotherapy. [europepmc]
• Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies. [europepmc]
• A 2A R eGFP reporter mouse enables elucidation of A 2A R expression dynamics during anti-tumor immune responses. [europepmc]
• CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer. [europepmc]
• Targeting metabolism to improve CAR-T cells therapeutic efficacy. [europepmc]
• Engineering strategies to safely drive CAR T-cells into the future. [europepmc]
• Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments. [europepmc]
• Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment. [europepmc]
• Current perspectives and trends of CD39-CD73-eAdo/A2aR research in tumor microenvironment: a bibliometric analysis. [europepmc]
• Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment. [europepmc]
• Applying metabolic control strategies to engineered T cell cancer therapies. [europepmc]
• Mesothelin as a Signal Pathways and Epigenetic Target in Cancer Therapy. [europepmc]
• Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment. [europepmc]
• Improving CAR T cell therapy against malignancies through gene knock-down/out strategies: a systematic review. [europepmc]
• Monoclonal Antibodies and Derivatives: Therapeutic Tools for Cancer. [europepmc]